Examination of methylation changes of VIM, CXCR4, DOK7, and SPDEF genes in peripheral blood DNA in breast cancer patients

Shirkavand, Atefeh; Boroujeni, Zahra Niki; Aleyasin, Seyed Ahmad

doi:10.4103/ijc.ijc_100_18

Cited by 11 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We further showed that DOK7 serves as a negative regulator of JAK signaling pathway in BLCA cells. In agreement with our data, DOK7 was reported as a tumor suppressor in glioma, breast and lung cancer [19,20,[30][31][32][33]. For example, DOK7 was found to be down-regulated in lung cancer and its reduced expression was associated with the poor survival in lung cancer patients [30][31][32].…”

Section: Discussionsupporting

confidence: 91%

DOK7, a target of miR-299-5p, suppresses the progression of bladder cancer

Tian,

Liu,

et al. 2023

Aging

View full text Add to dashboard Cite

Objective: Bladder cancer (BLCA) is the 6th most common malignancy in males. microRNA (miRNAs) can function as tumor suppressors or oncogenic factors, which are of significance in the progression of BLCA. This study explored the mechanisms by which miR-299-5p modulates DOK7 (Docking Protein 7) expression and the functional role of DOK7 in the progression of BLCA. Methods: The expression of the DOK7 in BLCA patient samples was examined by RT-qPCR (Real-time quantitative polymerase chain reaction), Western blotting and Immunohistochemical (IHC) staining. The malignant phenotype of BLCA cells upon DOK7 overexpression or silencing was assessed by functional assays including cell count kit-9 (CCK8), colony formation and 5-ethynyl-2'-deoxyuridine (Edu) staining assays, as well as Transwell migration and invasion assays. The miRNA regulators of DOK7 were identified through bioinformatics prediction, and the biological role of miR-299-5p/DOK7 axis was validated by functional assays. The impact of miR-299-5p/DOK7 axis on Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway was further examined by Western blotting. Results: DOX7 was significantly downregulated in BLCA tumor tissues compared with normal tissues. Ectopic DOK7 expression suppressed the proliferation, migration and invasion of BLCA cells. DOK7 overexpression also attenuated the tumorigenesis of BLCA cells in nude mice. miR-299-5p was a negative regulator of DOK7 expression in BLCA cells. miR-299-5p/DOK7 axis impaired the malignancy of BLCA cells through regulating the JAK signaling pathway. Conclusion: Our data indicate that miR-299-5p/DOK7 axis suppresses BLCA progression possibly by regulating the JAK signaling pathway.

show abstract

Section: Discussionsupporting

confidence: 91%

DOK7, a target of miR-299-5p, suppresses the progression of bladder cancer

Tian,

Liu,

et al. 2023

Aging

View full text Add to dashboard Cite

show abstract

“…In addition, the gene expression of CXCR4 is strongly affected by methylation modification. DNA hypomethylation in the CXCR4 gene has been observed in breast cancer [ 101 ], colorectal cancer [ 102 ], pancreatic cancer [ 103 ] and melanoma [ 104 ], and this is associated with tumor progression. Although it has not been reported in prostate cancer, there is evidence that CXCR4 is affected by epigenetic modification in metastatic prostate cancer.…”

Section: Epigenetic Modifications In Tumor Microenvironment (Tme)mentioning

confidence: 99%

Epigenetic Modifications in Prostate Cancer Metastasis and Microenvironment

Zhang

Shen

Zeng

2023

Cancers

View full text Add to dashboard Cite

The gradual evolution of prostate tissue from benign tumor to malignant lesion or distant metastasis is driven by intracellular epigenetic changes and the tumor microenvironment remodeling. With the continuous study of epigenetic modifications, these tumor-driving forces are being discovered and are providing new treatments for cancer. Here we introduce the classification of epigenetic modification and highlight the role of epigenetic modification in tumor remodeling and communication of the tumor microenvironment.

show abstract

“…One of the most promising of these biomarkers is cell-free DNA (cfDNA), first described in 1948 [2]. The cfDNA profile corresponds with the metastatic model and disease progression; it can also reflect co-morbidity and resistance mechanisms, as well as the complete cancer gene expression profile and tumor staging [3][4][5][6][7][8][9]. cfDNA also includes circulating tumor DNA (ctDNA) referred to as the tumor code in the blood [10]; however, the ctDNA is mixed with a wide range of cfDNA from various sources and is hence difficult to detect clearly.…”

Section: Introductionmentioning

confidence: 99%

A comparison of four commercial kits used for isolating circulating cell-free DNA: QuickGeneMINI8L (Kurabo), Maxwell RSC cfDNA Plasma Kit (Promega), cfKapture 21 Kit (MagBio), and QIAamp MinElute ccfDNA Kit (Qiagen)

Boguszewska-Byczkiewicz

Jarych²,

Dróźdż

et al. 2020

Medical Research Journal

View full text Add to dashboard Cite

A minimally-invasive alternative to surgical biopsies is a liquid biopsy (LB), a technique that has recently revolutionized the management of a number of tumors. One potential target biomarker of LB is cell-free DNA (cfDNA), which can act as a very sensitive indicator for certain tumors. Currently, clinical efforts are focused on increasing the quality of the cfDNA isolated for analysis. The present study compares the efficiency of isolation by four commercial kits: QuickGeneMINI8L (Kurabo), Maxwell RSC cfDNA Plasma Kit (Promega), cfKapture 21 Kit (MagBio), and QIAamp MinElute ccfDNA Kit (Qiagen). In each case, cfDNA was isolated from three plasma samples and one serum sample. Available method for the isolation give the ability to enrich optimal diagnostic quantity of cfDNA. cfDNA can be successfully separated using all investigated kits. The greatest efficiency was demonstrated by the QIAamp MinElute ccfDNA Kit (Qiagen) and cfKapture 21 (MagBio). Large amounts of cell-free DNA can be successfully isolated from small volumes of plasma.

show abstract

Examination of methylation changes of VIM, CXCR4, DOK7, and SPDEF genes in peripheral blood DNA in breast cancer patients

Cited by 11 publications

References 28 publications

DOK7, a target of miR-299-5p, suppresses the progression of bladder cancer

DOK7, a target of miR-299-5p, suppresses the progression of bladder cancer

Epigenetic Modifications in Prostate Cancer Metastasis and Microenvironment

A comparison of four commercial kits used for isolating circulating cell-free DNA: QuickGeneMINI8L (Kurabo), Maxwell RSC cfDNA Plasma Kit (Promega), cfKapture 21 Kit (MagBio), and QIAamp MinElute ccfDNA Kit (Qiagen)

Contact Info

Product

Resources

About